Home › Research › Health systems and care delivery
Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers
Burns Jeffrey M, Alford Susan, Coppinger Justine, Jiménez-Mausbach Martí, Ray Sutapa, Pandey Hemant, Laird Rosemary. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-01-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We aimed to explore primary care physicians' (PCP) attitudes, perceptions, and barriers toward Alzheimer's disease (AD) diagnosis and incorporating blood biomarker (BBM) tests into the diagnostic workflow. Remote 60-min interviews with 20 PCPs were conducted (May 2023). Participants included generalists and geriatricians representing urban, suburban, and rural U.S. practices. Interviews encompassed early AD diagnosis, PCP role, and BBM test implementation. Most PCPs view investigating cognitive decline as an important part of their role and are somewhat confident in diagnosing AD. Barriers include the complexity and inefficiency of current diagnostic workflows, lack of effective treatments, and stigma. PCPs consider BBM tests accurate and cost-effective but have concerns about reimbursement and diagnostic pathway placement. PCPs are interested in AD diagnosis and receptive toward BBM testing. Education on BBM test use and AD diagnosis may benefit PCPs in the care of individuals with cognitive decline. Early Alzheimer's disease (AD) diagnosis is crucial for initiating treatment Primary care physicians (PCPs) find investigation of cognitive decline important PCPs consider blood biomarker (BBM) tests accurate and cost-effective PCPs seek clarity on reimbursement of BBM tests and their context of use Education on BBM test interpretation and AD diagnosis may benefit primary care.
What this study adds
Evidence grade: Low
This interview study reports that U.S. primary care physicians are interested in Alzheimer's disease diagnosis and receptive to blood biomarker testing, but face barriers including complex diagnostic workflows, lack of effective treatments, stigma, and reimbursement concerns. It does not evaluate any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burns Jeffrey, M., Susan, A., Justine, C., Martí, J.-M., Sutapa, R., Hemant, P., et al. (2026). Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70986
Vancouver
Burns Jeffrey M, Susan A, Justine C, Martí J.-M, Sutapa R, Hemant P, et al. Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.70986. PMID: 41549413.
BibTeX
@article{burnsjeffrey2026-41549413,
author = {Burns Jeffrey, M. and Susan, Alford and Justine, Coppinger and Martí, Jiménez-Mausbach and Sutapa, Ray and Hemant, Pandey and Rosemary, Laird},
title = {{Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.70986},
pmid = {41549413},
url = {https://doi.org/10.1002/alz.70986}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Barriers include the complexity and inefficiency of current diagnostic workflows, lack of effective treatments, and stigma.
- PCPs consider BBM tests accurate and cost-effective but have concerns about reimbursement and diagnostic pathway placement.
- PCPs are interested in AD diagnosis and receptive toward BBM testing.
- Education on BBM test use and AD diagnosis may benefit PCPs in the care of individuals with cognitive decline.
- Early Alzheimer's disease (AD) diagnosis is crucial for initiating treatment Primary care physicians (PCPs) find investigation of cognitive decline important PCPs consider blood biomarker (BBM) tests accurate and cost-effective PCPs seek clarity on reimbursement of BBM tests and their context of use Education on BBM test interpretation and AD diagnosis may benefit primary care.
Why it matters
This interview study reports that U.S. primary care physicians are interested in Alzheimer's disease diagnosis and receptive to blood biomarker testing, but face barriers including complex diagnostic workflows, lack of effective treatments, stigma, and reimbursement concerns. It does not evaluate any treatment, cure, or prevention.
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-17) |
| Citations per year | 2 / 5 | 3.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 31.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Rosemary D. Laird: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Kansas Medical Center: institution h-index 577 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41549413) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.